A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationJohn T. Brandt, Kenneth J. Winters, Christopher D. Payne et al.|American Heart Journal|2006Cited by 571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Lars Wallentin, Christopher D. Payne et al.|European Heart Journal|2006Cited by 537
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseLars Wallentin, Agneta Siegbahn, Christoph Varenhorst et al.|European Heart Journal|2007Cited by 457
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyNazar Farid, Daniel E. Salazar, Christopher D. Payne et al.|Clinical Pharmacology & Therapeutics|2007Cited by 323
Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet ProfileJoseph A. Jakubowski, Lars Wallentin, Kenneth J. Winters et al.|Cardiovascular Drug Reviews|2007Cited by 249